NCT00263315View on ClinicalTrials.gov

Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

January 31, 2000

Study Completion Date

May 31, 2006

Conditions
Aspergillosis
Interventions
DRUG

nebulised liposomal amphotericin B

Trial Locations (2)

Unknown

Erasmus MC centrumlocatie, Rotterdam

Erasmus MC locatie Daniel den Hoed, Rotterdam

Sponsors
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

collaborator

Nexstar Pharmaceuticals

INDUSTRY

lead

Erasmus Medical Center

OTHER